Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661166 · ClinicalTrials.gov registry record · Phase 4
A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy
A Phase 4 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT01661166 is a Phase 4 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 3 participants.
The verdict
NCT01661166, a Phase 4 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients. Additionally, the correlation between OAB symptoms and urodynamic DO will be analyzed.
Interventions
- DRUG Placebo oral tablet
- DRUG Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-04-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01661166
The ClinicalTrials.gov registry entry for NCT01661166 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT01661166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01661166 about?
NCT01661166 is a clinical study titled "A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy". The investigators will assess the incidence of Overactive Bladder/Detrusor Overactivity (OAB/DO) post-operatively in patients post robotic assisted radical prostatectomy (RARP) and to investigate whether fesoterodine will alter the incidence of OAB/DO in these patients. Additionally, the correlation...
What is the current status of trial NCT01661166?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2012-01. Estimated completion is 2013-04-15.
What interventions are being tested in trial NCT01661166?
The interventions under investigation include: Placebo oral tablet (DRUG), Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT01661166?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.